"Pharmaceutical Speed Reader" Kaixin as far as 38 million U.S. dollars to raise three generic drugs were approved.

July 24, 2020 / Medical Information At a Glance: Kaixin Yuanda completed a $38 million financing targeting Chinese patients in the field of hematoma; Favipiravir treatment of patients with light and moderate new crowns in small, medium-sized, phase 3 clinical reached the main end point; innovative cardiomyopathy targeted therapy was recognized by the FDA for breakthrough therapy; and the National Drug Administration announced: a batch of drugs discontinued, recalled... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Briefing State Drug Administration Notice: a batch of drug sales, recall 23, the State Drug Administration issued "on 25 batches of drugs do not comply with the provisions of the notice", the notice shows that by the Henan Province Food and Drug Inspection Institute and other 9 drug inspection institutions, marked as Jiangsu Wu Chinese Medicine Group Co., Ltd. Suzhou Pharmaceutical Factory and other 14 pharmaceutical manufacturers produced 25 batches of drugs do not meet the requirements.
(National Drug Administration) Part 2 Production observation G1 and EQRx on the licensing interest of lerociclib, G1 announced a licensing agreement with EQRx.
under the terms of the agreement, EQRx acquires exclusive rights to lerociclib in the United States, Europe, Japan and all other global markets (excluding Asia Pacific (excluding Japan).
in return, G1 will receive an upfront cash payment of $20 million and is eligible for $290 million in development and commercial milestone payments, as well as royalties based on the annual net sales of lerociclib.
(Sina Pharmaceutical News) Kaixin Yuanda completed a $38 million financing targeting Chinese patients in the field of hematoma recently, Kaixin Yuanda announced that through a non-public offering of 20 million shares of common stock to raise a total of about 38 million U.S. dollars.
, a NASDAQ-listed biopharmaceutical company dedicated to providing advanced disease treatment programs for Chinese patients in the field of blood tumors, has wholly-owned subsidiaries and production and research and development centers in Beijing and Wuxi.
(Pharmaceutical Mission) Part 3 Pharmaceutical Information Favipiravir Treatment Ofavipiravir Treatment Of Small Medium New Crown Patients Phase 3 Clinical End Recently, Glenmark developed the antiviral drug Favipiravir generic fabiFlu, in a Phase 3 clinical study showed accelerated recovery cycles in patients with mild to moderate symptoms of COVID-19. The latest results, released by
Glenmark, show that favipiravir increased the virus clearance rate by 28.6 percent to the primary endpoint compared to the placebo.
(Sina Pharmaceutical News) JAK inhibitors for the treatment of chronic transplant anti-host disease reached the clinical endpoint of Phase 3, Incyte announced that the jak1/2 inhibitor Jakafi, jointly developed by novartise, reached the primary endpoint in phase 3 clinical studies in the treatment of moderate or severe steroid-dependent chronic steroid refractive or steroid-dependent chronic transplant resistance host patients, with a better total remission rate (ORR) in week 24 compared to best available therapy (BAT).
(drug Mingkang) herb Octopus "first-in-class" brain tumor new drug completed the first patient administration 23, herb Octopus announced that it was in the new drug NBQ72S in the treatment of advanced malignant tumors in the first phase of clinical trials to complete the first patient-administered drug.
NBQ72S is a new type of dual-function small molecule drug targeting human L-type amino acid transporter protein 1, which is the world's first new drug (first-in-class), to develop and treat malignant tumors such as brain tumors.
(Pharmaceutical Mission) Collon Pharmaceuticals "Hydrochloric acid defied the non-tablets" the first imitation approved Collon Pharmaceuticals 4 generic drugs hydrochloric acid dealionna non-tablets approved by the State Drug Administration for listing, for the first domestic imitation. Developed by Bayer
, the non-original study of Valdina is a selective inhibitor of phosphodiesterase 5, which, like Dalafi and Sida, is taken on demand to address erectile dysfunction in men.
(Pharmaceutical Rubik's Cube) Nanjing Zhengda Qing 3 generic drugs approved Nanjing Zhengda Qing 3 4 types of generic drugs (Apixa ban tablets, radon acid tofati cloth tablets, injection of hydrochloric acid Idabi Star) approved by the State Drug Administration for listing, as the same through the consistency evaluation.
, the apixaban tablets and the tofatibib sheet of acetic acid were the third batch of national collection varieties, while the injection of idabite hydrochloric acid was the first to pass the consistency evaluation.
(Pharmaceutical Rubik's Cube) Stone Pharmaceutical Group antidepressant "Hydrochloric luositine intestinal lysis capsule" approved stone pharmaceutical group according to the new 4 categories of hydrochloric acid lositin intestinal dissolved capsule seyroly capsule seinometer listing application was approved by the State Drug Administration for listing, as is the same as through the consistency evaluation.
this is the second domestic manufacturer of the drug to pass consistency evaluation after Bete Pharmaceuticals.
(Pharmaceutical Rubik's Cube) Jingxin Pharmaceuticals "Paskso Hydrochloric Acid Slow Release Tablet" the first approved Beijing New Pharmaceutical Industry 4 class of generic drug Praxoso slow release tablets approved by the State Drug Administration for listing, the first domestic manufacturer of the drug approved, and regarded as the same through the consistency evaluation.
Plaxopers re-release tablets are used to treat the signs and symptoms of iexclusiveist Parkinson's disease, either alone or in conjunction with lvocyclodobar.
(Pharma Cube) Shangjian biological CD38 single anti-declaration clinical and received the latest nMPA publicity, ShangJian bio 1 new drug CD38 single anti-declaration clinical and accepted.
this is the company's second product to submit a clinical trial to NMPA, the first of which, PD-1 antibodies, was approved for clinical use in November 2018.
(NMPA) Innovative Cardiomyopathy Targeted Therapy was recognized by the FDA Breakthrough Therapy Myo Kardia, and the U.S. FDA has awarded the company's mavacamten breakthrough therapy for the treatment of symptomatic, obstructive hypertrophy.
Mavacamten is an innovative oral myocardial myoglobin deflator that is expected to reduce the symptoms of excessive cardiac contraction in patients.
(Drug Mingkang) cornerstone pharmaceutical PD-1 antibodies by the U.S. FDA awarded orphan drug eligibility cornerstone pharmaceutical industry announced that the U.S. FDA has awarded its PD-1 antibody CS1003 orphan drug eligibility for the treatment of liver cell carcinoma.
CS1003 is one of the products of tumor immunoskeleton in Keystone Pharmaceuticals, and has carried out a number of clinical studies on joint treatment, of which CS1003 joint levalinib is the first line of treatment of patients with advanced liver cancer, the global multi-center 3 registered clinical research is in the group.
(Pharmaceutical Mission) Long Chain Fatty Acid Oxidation Metabolic Disease Drug Dojolvi recently launched in the United States, Ultragenyx announced that Dojolvi is now on the market, the drug was approved by the U.S. FDA at the end of June this year as a source of calories and fatty acids, for the treatment of molecularly tested long-chain fatty acid oxidation metabolic disease (LC-FAOD) in children and adult patients.
Dojolvi was the first FDA-approved drug to treat LC-FAOD, marking a major milestone in the treatment of the disease.
(BioValley) Xinlitai Repamycin Drug Eluthetic Arterial Stent System obtained medical device registration certificate Xinlitai issued a notice that the company's subsidiary Yallen Bio received the Approval issued by the State Drug Administration, "Rapamycin Drug Removal Vertebral Arterial Stent System" (Maurora ®) "Medical device registration certificate."
the product is a combination of severely clinically proven reperacycin drugs that are clinically proven in the intracranial artery and vertebral artery, which is suitable for the stenosis expansion of the excranial excranial segment of the symptomatic vertebral artery.
(Xinlitai Announcement) Cell: Qin Chengfeng/Inbeg/Wang Youchun team developed a new mRNA new crown vaccine "Cell" magazine published an online article on the new crown vaccine.
a team led by Qin Chengfeng, Dr. Inbee and Wang Youchun has developed a new type of mRNA new crown vaccine.
in mouse and non-human primate models, the vaccine stimulates an immune response and induces the production of neutralizing antibodies.
(Academic Latitude)